Moderna, Inc. recently hosted a highly anticipated conference call to discuss groundbreaking Phase III clinical data for its investigational cancer immunotherapy, intismeran, while outlining broader advancements in the rapidly evolving field of oncology. The presentation, held on October 24, 2026, brought together key company executives, lead clinical investigators, and world-renowned experts in melanoma and cancer immunology to evaluate the potential paradigm shift that personalized neoantigen therapies could bring to cancer treatment.
David Berman, Chief Development Officer at Moderna, opened the executive presentation by framing the significance of the clinical update for both the scientific community and the patients awaiting new therapeutic options. Addressing the participants, Berman captured the gravity of the occasion, calling it a watershed moment for the future of oncology.
"Good evening, and thank you for joining us today," Berman stated at the onset of the call. "This is a very exciting day for cancer patients, it’s an exciting day for cancer immunologists, and it’s an exciting day for Moderna."
Following a standard forward-looking statement regarding regulatory hurdles, clinical timelines, and financial projections, Berman outlined the structure of the briefing. He explained that he would first provide contextual background on intismeran and its underlying mechanism of action before inviting Dr. Georgina Long, the lead investigator for the pivotal INTerpath-001 clinical trial, to deliver a reprise of her comprehensive presentation. The session was also designed to feature expert commentary from a distinguished panel, including Professor Paolo Ascierto, the senior author of the INTerpath-001 study, and Professor Antoni Ribas, a globally recognized leader in melanoma and cancer immunotherapy.
To understand the enthusiasm surrounding intismeran, Berman dove deep into the biological mechanics of immune surveillance, detailing how the human body naturally attempts to detect and eradicate malignant cells. Immune surveillance relies fundamentally on the body’s ability to recognize aberrant proteins, known as neoantigens, which form exclusively within cancer cells as a result of genetic mutations.
Berman walked the audience through the intricate biological cascade that must occur for the immune system to successfully combat a tumor. Under normal physiological conditions, these neoantigens are released from dying or stressed cancer cells and are subsequently drained or carried through the lymphatic system to regional lymph nodes. Once inside the lymph nodes, the neoantigens are processed by specialized antigen-presenting cells. These cells then internalize, process, and present the neoantigen fragments on their outer surface, displaying them to naïve and memory T cells.
When T cells successfully recognize these presented neoantigens as foreign or abnormal, they undergo rapid activation and proliferation. These activated T cells then circulate systematically throughout the body via the bloodstream and lymphatic vessels, actively hunting down and eliminating cancer cells that express the corresponding neoantigens. In an ideal scenario, this creates a sustained, highly targeted immune response capable of keeping emerging malignancies at bay.
However, as Berman emphasized, cancer is a notoriously adaptable adversary that has evolved multiple mechanisms to evade and suppress this intricate immune surveillance network. Tumors frequently manage to slip past the body’s defenses through several distinct pathways. In some instances, a cancer may simply lack a sufficient number or variety of recognizable neoantigens, effectively acting as an immunological ghost that fails to trigger a robust T-cell response. In other cases, even if neoantigens are present, they may not be adequately released from the tumor microenvironment or efficiently transported to the draining lymph nodes. Furthermore, disruptions can occur further down the line, such as when antigen-presenting cells fail to properly process the material or adequately display the fragments on their cellular surfaces to prime the T cells.
By detailing these biological checkpoints, Berman laid the groundwork for understanding how targeted therapies like intismeran are designed to intervene, overcome these specific immune escape routes, and reactivate the patient’s intrinsic cellular defense mechanisms against advanced malignancies. The insights shared during the conference call underscored Moderna’s broader strategic commitment to leveraging messenger RNA technology not only for infectious diseases, but to create highly customized, patient-specific weapons in the ongoing war against cancer.
